Sign up to save your podcasts
Or
Share Democratizing AI for Biology | Discovery Engines
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Democratizing AI for Biology | Discovery Engines
Gabriele Corso, CEO and co-founder of Boltz, believes the most powerful AI models for drug discovery should be accessible to all, starting with the open models his team has put in the hands of over 100,000 scientists. In this episode, I sit down with Gabriele to explore the leap from predicting protein structures to designing new molecules with Boltz-1, Boltz-2, and BoltzGen, why he champions open access, their multi-year partnership with Pfizer, and the vision of "zero-shot" drug design.
Hosted by Nabil Laoudji. See below for episode links, chapters, and our socials. 🙏🙌
Episode Links:
- Boltz
- Boltz Repository
- Gabriele's LinkedIn
- Worldwide Protein Data Bank
- Ginkgo Lab Tour
- Pfizer Partnership Announcement
Chapters:
- (00:00) - Preview
- (00:56) - Intro
- (02:15) - Why Proteins Matter and Rational Drug Design
- (05:51) - Target Identification, the Toughest Problem in Drug Discovery
- (07:55) - Small Molecules and Biologics
- (12:57) - Does a Disease Have One Target or Many?
- (15:36) - The Billion Dollar Molecule and How Boltz's Models Work
- (22:05) - The Protein Data Bank (PDB) and the Role of Sequencing Data
- (25:55) - What New Data Could Improve AI Bio Models?
- (29:02) - Where Boltz's Training Data Comes From
- (31:46) - Unlocking Private Bio Data
- (35:34) - Boltz's Open Approach vs. DeepMind's Isomorphic Labs
- (39:18) - What Boltz's 100,000 Users Get Access To
- (41:32) - Inside the Pfizer Partnership
- (43:55) - Why Biotech Business Models Are So Hard (Microsoft, Apple, Red Hat)
- (49:17) - How Boltz Differs from Schrödinger, Recursion and Others
- (52:31) - Regulation, the FDA, and Trust in Computational Data
- (56:42) - Autonomous Labs and the Data Feedback Loop
- (1:00:25) - Faster Trials, Virtual Cells, and Other Speedups
- (1:03:34) - When Will a Boltz-Designed Drug Reach a Patient?
- (1:04:55) - How Listeners Can Help (Hiring, Partnerships, Investing)
- (1:06:27) - Closing Reflections on Access
Connect With Us:
- Our Newsletter
- Bluesky
- Feedback or questions
Platforms:
- YouTube
- Apple Podcasts
- Spotify Podcasts
View all episodes
By Nabil Laoudji, YesAnd Labs LLCGabriele Corso, CEO and co-founder of Boltz, believes the most powerful AI models for drug discovery should be accessible to all, starting with the open models his team has put in the hands of over 100,000 scientists. In this episode, I sit down with Gabriele to explore the leap from predicting protein structures to designing new molecules with Boltz-1, Boltz-2, and BoltzGen, why he champions open access, their multi-year partnership with Pfizer, and the vision of "zero-shot" drug design.
Hosted by Nabil Laoudji. See below for episode links, chapters, and our socials. 🙏🙌
Episode Links:
- Boltz
- Boltz Repository
- Gabriele's LinkedIn
- Worldwide Protein Data Bank
- Ginkgo Lab Tour
- Pfizer Partnership Announcement
Chapters:
- (00:00) - Preview
- (00:56) - Intro
- (02:15) - Why Proteins Matter and Rational Drug Design
- (05:51) - Target Identification, the Toughest Problem in Drug Discovery
- (07:55) - Small Molecules and Biologics
- (12:57) - Does a Disease Have One Target or Many?
- (15:36) - The Billion Dollar Molecule and How Boltz's Models Work
- (22:05) - The Protein Data Bank (PDB) and the Role of Sequencing Data
- (25:55) - What New Data Could Improve AI Bio Models?
- (29:02) - Where Boltz's Training Data Comes From
- (31:46) - Unlocking Private Bio Data
- (35:34) - Boltz's Open Approach vs. DeepMind's Isomorphic Labs
- (39:18) - What Boltz's 100,000 Users Get Access To
- (41:32) - Inside the Pfizer Partnership
- (43:55) - Why Biotech Business Models Are So Hard (Microsoft, Apple, Red Hat)
- (49:17) - How Boltz Differs from Schrödinger, Recursion and Others
- (52:31) - Regulation, the FDA, and Trust in Computational Data
- (56:42) - Autonomous Labs and the Data Feedback Loop
- (1:00:25) - Faster Trials, Virtual Cells, and Other Speedups
- (1:03:34) - When Will a Boltz-Designed Drug Reach a Patient?
- (1:04:55) - How Listeners Can Help (Hiring, Partnerships, Investing)
- (1:06:27) - Closing Reflections on Access
Connect With Us:
- Our Newsletter
- Bluesky
- Feedback or questions
Platforms:
- YouTube
- Apple Podcasts
- Spotify Podcasts